Polycythemia diagnostic study of choice

Jump to navigation Jump to search

Polycythemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia diagnostic study of choice

CDC on Polycythemia diagnostic study of choice

Polycythemia diagnostic study of choice in the news

Blogs on Polycythemia diagnostic study of choice

Directions to Hospitals Treating Polycythemia

Risk calculators and risk factors for Polycythemia diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]

Overview

Diagnostic study of choice for polycythemia includes history and physical examination. Blood evaluation in association with genetic mutation study for relevant mutation. Imaging for splenomegaly.

Diagnostic Study of Choice

Study of choice

Diagnostic criteria for polycythemia vera:[5]

A1.Hematocrit >0.52 in men, >0.48 in women OR; red cell mass >25% above predicted. A2.Mutation in JAK2

  • Both criteria must be present for a diagnosis.

A1. Increased RBC mass >25% above predicted OR; Hct >0.60 in men and >0.56 in women. A2.Absence of a JAK2 mutation. A3.Absent secondary erythrocytosis causes. A4.Splenomegaly is palpable on physical examination. A5.Evidence of an acquired mutation (except BCR-ABL) in the hematopoietic cells. B1.Thrombocytosis (>450 x 109) B2. Neutrophilic leukocytosis (>10 x 109 in smokers, >12.5 x 109 in non-smokers). B3.Evidence of splenomegaly on imaging. B4.Reduced serum erythropoietin or colonies of endogenous erythroid cells.

A1 + A2 + A3 plus either one more A or two B criteria must be present for diagnosis.

References

  1. Streiff MB, Smith B, Spivak JL (2002). "The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns". Blood. 99 (4): 1144–9. doi:10.1182/blood.v99.4.1144. PMID 11830459.
  2. Raedler LA (2014). "Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable". Am Health Drug Benefits. 7 (7 Suppl 3): S36–47. PMC 4639938. PMID 26568781.
  3. Thiele J, Kvasnicka HM (January 2005). "Diagnostic impact of bone marrow histopathology in polycythemia vera (PV)". Histol Histopathol. 20 (1): 317–28. doi:10.14670/HH-20.317. PMID 15578448.
  4. Thiele J, Kvasnicka HM, Zankovich R, Diehl V (April 2001). "The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias". Haematologica. 86 (4): 368–74. PMID 11325641.
  5. Griesshammer M, Gisslinger H, Mesa R (2015). "Current and future treatment options for polycythemia vera". Ann Hematol. 94 (6): 901–10. doi:10.1007/s00277-015-2357-4. PMC 4420843. PMID 25832853.

Template:WH Template:WS